French biotech, Samabriva, has unveiled a significant expansion with a new 1,400-square-meter biomanufacturing facility located in Liege, Belgium, to aid the transition from research and development to industrial-scale production. The state-of-the-art facility is equipped with proprietary bioreactors specifically designed for hairy root culture, enabling the production of natural molecules for pharmaceutical applications.

Set to become operational in Q1 2025, the facility will create new employment opportunities in the bioproduction, analytics, and quality assurance sectors, while the new facility promises enhanced control over the biomanufacturing process, for a cost-effective and sustainable alternative to traditional open field production methods.

The following article originally appeared in European Pharmaceutical Manufacturer.

This strategic investment strengthens Samabriva’s position as a leading player in the region’s thriving biomanufacturing ecosystem.

This multi-million Euros investment is designed to provide industrial scale production of high value natural molecules* used in the manufacture of pharmaceutical products. Equipped with Samabriva’s proprietary bioreactors, which have been specifically designed to maximise production in hairy root culture, the facility will enhance efficiency and output.

This announcement represents the next step in Samabriva’s growth strategy, marking the transition to industrial production following a decade of research and development. Phase one of the facility will be operational by Q1 2025 to meet the demands of the company’s first commercial international customers.

In addition to providing advanced manufacturing, the facility will create several new jobs across bioproduction, analytics and quality assurance, contributing to global economic growth. It will also provide customers with full control over the biomanufacturing process, offering a cost effective and sustainable alternative to open field production.

Pascal Lizin, chairman of the board of Samabriva - "This new facility represents a significant milestone for Samabriva. It emphasises our commitment to delivering plant-based bioproduction at large scale. By offering control over the entire value chain, the facility has the potential to transform production of high value molecules – delivering them more cost-effectively to international customers, when and where they’re needed."

Bertrand Duquesne, COO and QP for Samabriva Biomanufacturing said: “We are delighted to be implementing the high potential manufacturing platform that Samabriva has been developing over the last ten years on an industrial scale. The platform will enable GMP quality production of molecules of interest for our current and future customers”.

For more, please find the original story source here.